Keyphrases
Acute Coronary Event
6%
Adverse Events
7%
Age-friendly
8%
Age-friendly Care
9%
Age-Friendly Health Systems
6%
Aging
10%
AIDS/HIV
7%
Air Force
24%
Alzheimer's Disease
47%
Antiretroviral Therapy
13%
Atherosclerosis Prevention
24%
C-reactive Protein
6%
Canada
8%
Cardiorespiratory Responses
9%
CD4 Count
7%
CD4+
7%
CD8+ T Cells
14%
Cerebral Perfusion
9%
Cholesterol
17%
Clinical Outcomes
6%
Confidence Interval
19%
Coronary Atherosclerosis
24%
Dementia
15%
Directly Observed Therapy
15%
Drug Resistance
7%
Elderly Adults
6%
Elderly Patients
9%
Elderly People
7%
Experiential Learning Activities
9%
Fall Prevention
9%
Gemfibrozil
9%
Genotype
7%
Geriatric Education
10%
Geriatric Workforce
7%
Geriatrics
11%
Health Care Costs
6%
Health Equity
6%
Heart Rate
18%
High Risk
11%
High-density Lipoprotein Cholesterol (HDL-C)
20%
HIV Infection
8%
HIV Patients
11%
HIV-related
6%
Immunization
6%
Immunosuppressive Therapy
7%
Intervention Group
9%
Intracellular Pathogen
7%
IS6110
6%
Latent Tuberculosis Infection
27%
LDL Cholesterol
8%
Lovastatin
23%
Low-density Lipoprotein Cholesterol (LDL-C)
16%
Low-density Lipoprotein Cholesterol Level
7%
Major Coronary Events
11%
Mean Arterial Pressure
9%
Mentation
8%
Mexican Americans
12%
Mild Cognitive Impairment
13%
Monocytes
6%
Multidrug-resistant Tuberculosis (MDR-TB)
8%
Muscle Symptoms
6%
Mycobacterium Tuberculosis (M. tb)
43%
Mycobacterium Tuberculosis Infection
6%
Neuropsychiatric Symptoms
9%
Odds Ratio
11%
Older Adults
29%
Older Patients
6%
Older Persons
7%
Older Women
6%
Once-weekly
8%
Osteopathic
7%
Osteopathy
10%
Pathophysiology
6%
Physical Therapy Students
8%
Placebo
15%
Prevention Studies
24%
Primary Care
7%
Primary Prevention
10%
Pulmonary Dysfunction
15%
Pulmonary Tuberculosis
18%
Randomized Clinical Trial
7%
Relative Risk
10%
Rifapentine
18%
Risk Factors
10%
SMART Study
6%
Statin Therapy
12%
Statins
9%
Systemic Hypotension
6%
T Cells
12%
Texas
49%
Tolerability
6%
Treatment Completion
7%
Treatment Group
7%
Tuberculin Skin Test
13%
Tuberculosis
100%
Tuberculosis Control
6%
Tuberculosis Diagnosis
12%
Tuberculosis Patients
19%
Tuberculosis Treatment
25%
United States
33%
Medicine and Dentistry
Alzheimer's Disease
7%
Anus Carcinoma
6%
Brain Perfusion
9%
Breathing Rate
6%
Cardiorespiratory
9%
Cell Count
6%
Clinical Trial
7%
Directly Observed Therapy
12%
Disease
35%
Drug Resistance
6%
Drug Therapy
15%
Elderly Patient
6%
Fall Prevention
9%
Foreign Born
7%
Gastroesophageal Reflux
6%
Geriatrics
16%
Glycemic Control
6%
Health Care Cost
16%
Health System
6%
High Density Lipoprotein Cholesterol
7%
Human Immunodeficiency Virus
27%
Hypotension
6%
Hypoxemia
6%
Hypoxia
6%
Immigrant
6%
Infectious Disease Treatment
5%
Ingestion
6%
Intermittent Hypoxia
7%
Isoniazid
7%
Latent Tuberculosis
14%
Lovastatin
13%
Low Density Lipoprotein Cholesterol
7%
Lung
6%
Lung Tuberculosis
18%
Mantoux Test
5%
Maturity Onset Diabetes of the Young
6%
Mean Arterial Pressure
8%
Middle Cerebral Artery
5%
Mini-Mental State Examination
6%
Mycobacterium Tuberculosis
15%
Odds Ratio
6%
Pathogen
7%
Pathophysiology
6%
Placebo
11%
Prevalence
8%
Primary Health Care
16%
Primary Prevention
8%
Promoter Region
5%
Quality Improvement
7%
Restriction Fragment Length Polymorphism
7%
Skin Test
6%
T Cell
6%
Triage
6%
Tuberculin
6%
Tuberculosis
32%
Tuberculosis Treatment
10%